Enhancement of Anti-Tumor Effect of Particulate Vaccine Delivery System by ‘Bacteriomimetic’ CpG Functionalization of Poly-Lactic-Co-glycolic Acid Nanoparticles

References

• Gregory AE , TitballR , WilliamsonD . Vaccine delivery using nanoparticles . Front. Cell. Infect. Microbiol.3 , 13 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Li AV , MoonJJ , AbrahamWet al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination . Sci. Transl. Med.5 ( 204 ), 204ra130 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Blattman JN , GreenbergPD . Cancer immunotherapy: a treatment for the masses . Science305 ( 5681 ), 200 – 205 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y , GearySM , LemkeCDet al. Nanoparticle delivery systems in cancer vaccines . Pharm. Res.28 ( 2 ), 215 – 236 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sahoo SK , LabhasetwarV . Biodegradable plga/pla nanoparticles for anti-cancer therapy (chapter 14) . In : Nanotechnology For Cancer Therapy . AmijiMM ( Ed. ). CRC Press Taylor and Francis Group , FL, USA , 243 – 249 ( 2006 ).
   Google Scholar
• Schnurr M , GalambosP , ScholzCet al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines . Cancer Res.61 ( 17 ), 6445 – 6450 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Jaini R , KesarajuP , JohnsonJM , AltuntasCZ , Jane-WitD , TuohyVK . An autoimmune-mediated strategy for prophylactic breast cancer vaccination . Nat. Med.16 ( 7 ), 799 – 803 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Machluf N , ArnonR . Therapeutic MUC1-based cancer vaccine expressed in flagella – efficacy in an aggressive model of breast cancer . World J. Vaccines2 ( 3 ), 109 – 120 ( 2012 ).
   Google Scholar
• Fioretti D , IuresciaS , FazioVM , RinaldiM . DNA vaccines: developing new strategies against cancer . J. Biomed. Biotechnol.2010 , 174378 ( 2010 ).
   PubMedGoogle Scholar
• Baines J , CelisE . Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides . Clin. Cancer Res.9 ( 7 ), 2693 – 2700 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Carpentier A , Laigle-DonadeyF , ZoharSet al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma . Neuro Oncol.8 ( 1 ), 60 – 66 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mangsbo SM , NinalgaC , EssandM , LoskogA , TöttermanTH . CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4 T-cell immunity . J. Immunother.31 ( 1 ), 34 – 42 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Nikitczuk KP , SchlossRS , YarmushML , LattimeEC . PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival . J. Cancer Ther.4 ( 1 ), 280 – 290 ( 2013 ).
   PubMedGoogle Scholar
• Klippstein R , PozoD . Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies . Nanomedicine6 ( 4 ), 523 – 529 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Bode C , ZhaoG , SteinhagenF , KinjoT , KlinmanDM . CpG DNA as a vaccine adjuvant . Expert Rev. Vaccines10 ( 4 ), 499 – 511 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mueller M , ReichardtW , KoernerJ , GroettrupM . Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice . J. Control. Release162 ( 1 ), 159 – 166 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wang W , SinghM . Selection of adjuvants for enhanced vaccine potency . World J. Vaccines1 ( 2 ), 33 – 78 ( 2011 ).
   Google Scholar
• Abbas AK , LichtmanAH , PillaiS . Immunity to tumors (Chapter 17) . In : Cellular and Molecular Immunology (7th Edition) . SchmittB ( Ed. ). Elsevier/Saunders Co.MO, USA , 391 – 395 ( 2011 ).
   Google Scholar
• Thamake SI , RautSL , RanjanAP , GryczynskiZ , VishwanathaJK . Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy . Nanotechnology22 ( 3 ), 035101 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ranjan AP , ZeglamK , MukerjeeA , ThamakeS , VishwanathaJK . A sustained release formulation of chitosan modified PLCL: poloxamer blend nanoparticles loaded with optical agent for animal imaging . Nanotechnology22 ( 29 ), 295104 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Thamake SI , RautSL , GryczynskiZ , RanjanAP , VishwanathaJK . Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer . Biomaterials33 ( 29 ), 7164 – 7173 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Prasad S , CodyV , Saucier-SawyerJKet al. Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles . Pharm. Res.29 ( 9 ), 2565 – 2577 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Feldman JP . Quantitative methods inquires: a mathematical model for tumor volume evaluation using two-dimensions . J. Appl. Quant. Methods4 ( 4 ), 455 – 462 ( 2009 ).
   Google Scholar
• Manolova V , FlaceA , BauerM , SchwarzK , SaudanP , BachmannMF . Nanoparticles target distinct dendritic cell populations according to their size . Eur. J. Immunol.38 ( 5 ), 1404 – 1413 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Basavanhally A , GanesanS , FeldmanMet al. Multi-field-of-view framework for distinguishing tumor grade in ER breast cancer from entire histopathology slides . IEEE Trans. Biomed. Eng.60 ( 8 ), 2089 – 2099 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Belardelli F , FerrantiniM , ProiettiE , KirkwoodJM . Interferon-alpha in tumor immunity and immunotherapy . Cytokine Growth Factor Rev.13 ( 2 ), 119 – 134 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Dunn GP , KoebelCM , SchreiberRD . Interferons, immunity and cancer immunoediting . Nat. Rev. Immunol.6 ( 11 ), 836 – 848 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Martini M , TestiMG , PasettoMet al. IFN-γ-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer . Vaccine28 ( 20 ), 3548 – 3557 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Jackson Erica , SolimanHatem . Realizing the promise of breast cancer vaccines . Vaccine: Dev. Ther.2 , 35 – 41 ( 2012 ).
   Google Scholar
• Buonaguro L , PetrizzoA , TorneselloML , BuonaguroFM . Translating tumor antigens into cancer vaccines . Clin. Vaccine Immunol.18 ( 1 ), 23 – 34 ( 2011 ).
   PubMedGoogle Scholar
• Akagi T , BabaM , AkashiM . Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine . In : Advanced Polymer Science (247) Polymers in Nanomedicine . KunugiS , YamaokaT ( Ed. ). Springer-Verlag Berlin Heidelberg , London, New York, USA , 31 – 64 ( 2012 ).
   Google Scholar
• Prasad S , CodyV , Saucier-SawyerJKet al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based anti-tumor immunotherapy . Nanomedicine7 ( 1 ), 1 – 10 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hamdy S , HaddadiA , HungRW , LavasanifarA . Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations . Adv. Drug Deliv. Rev.63 ( 10 ), 943 – 955 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Blander JM , MedzhitovR . Toll-dependent selection of microbial antigens for presentation by dendritic cells . Nature440 ( 7085 ), 808 – 812 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Fischer S , SchlosserE , MuellerMet al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response . J. Drug Target.17 ( 8 ), 652 – 661 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• de Titta A , BallesterM , JulierZet al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose . Proc. Natl Acad. Sci. USA110 ( 49 ), 19902 – 19907 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kasturi SP , SkountzouI , AlbrechtRAet al. Programming the magnitude and persistence of antibody responses with innate immunity . Nature470 ( 7335 ), 543 – 547 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Pistel K , KisselT . Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique . J. Microencapsul.17 ( 4 ), 467 – 483 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Gnjatic S , SawhneyNB , BhardwajN . TLR agonists: are they good adjuvants?Cancer J.16 ( 4 ), 382 – 391 ( 2009 ).
   Web of Science ®Google Scholar
• Ding Z , ZhouG . Cytotoxic chemotherapy and CD4 . Clin. Dev. Immunol.2012 ( 2012 ).
   PubMedGoogle Scholar
• Ostrand-Rosenberg S . CD4 T lymphocytes: a critical component of anti-tumor immunity . Cancer Invest.23 ( 5 ), 413 – 419 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Melief CJ . ‘License to kill’ reflects joint action of CD4 and CD8 T cells . Clin. Cancer Res.19 ( 16 ), 4295 – 4296 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yo-Ping L , Chung-JiuanJ , Shu-ChingC . The roles of CD4 T cells in tumor immunity . ISRN Immunology2011 , 1 – 6 ( 2011 ).
   Google Scholar
• Zhang S , ZhangH , ZhaoJ . The role of CD4 T cell help for CD8 CTL activation . Biochem. Biophys. Res. Commun.384 ( 4 ), 405 – 408 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Yu MK , ParkJ , JonS . Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy . Theranostics2 ( 1 ), 3 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dermime S , ArmstrongA , HawkinsRE , SternPL . Cancer vaccines and immunotherapy . Br. Med. Bull.62 ( 1 ), 149 – 162 ( 2002 ).
   PubMedGoogle Scholar
• Formenti SC , DemariaS . Combining radiotherapy and cancer immunotherapy: a paradigm shift . J. Natl Cancer Inst.105 ( 4 ), 256 – 265 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hamby LS , McGrathPC . Improved survival with adjuvant immunotherapy after surgical resection in a murine model . Ann. Surg. Oncol.1 ( 4 ), 307 – 313 ( 1994 ).
   PubMed Web of Science ®Google Scholar